Genetic and environmental modifiers of Wilson disease

Valentina Medici, Karl Heinz Weiss

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Citations (Scopus)

Abstract

Wilson disease (WD) is characterized by remarkable variety in its phenotypic presentation. Patients with WD can present with hepatic, neurologic, and psychiatric symptoms combined in different and unpredictable ways. Importantly, no convincing phenotype–genotype correlation has ever been identified, opening the possibility that other genes, aside from ATPase copper-transporting beta (ATP7B), are involved in the pathogenesis of this condition. In addition, modifier genes, or genes that can affect the expression of other genes, may be involved. Clinical and basic science data indicate that environmental and dietary factors can potentially modify gene expression in WD and, consequently, its clinical presentation and course. In particular, previously studied genes include copper metabolism domain-containing 1 (COMMD1), antioxidant 1 copper chaperone (ATOX1), X-linked inhibitor of apoptosis (XIAP), apolipoprotein E (APOE), hemochromatosis (HFE), and 5,10-methylenetetrahydrofolate reductase (MTHFR). Dietary factors include iron and methyl group donors which could affect methionine metabolism and epigenetic mechanisms of gene expression regulation. Most of the work conducted in this field is in its initial stages but it has the potential to change the diagnosis and treatment of WD.

Original languageEnglish (US)
Title of host publicationHandbook of Clinical Neurology
PublisherElsevier B.V.
Pages35-41
Number of pages7
Volume142
DOIs
StatePublished - 2017

Publication series

NameHandbook of Clinical Neurology
Volume142
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Hepatolenticular Degeneration
Copper
Modifier Genes
Genes
Gene Expression
Methylenetetrahydrofolate Reductase (NADPH2)
Hemochromatosis
Gene Expression Regulation
Apolipoproteins E
Neurologic Manifestations
Epigenomics
Methionine
Psychiatry
Iron
Antioxidants
Tissue Donors
Apoptosis
Liver
Therapeutics

Keywords

  • epigenetics
  • gender
  • genes
  • iron
  • modifier genes
  • Wilson disease

ASJC Scopus subject areas

  • Medicine(all)
  • Neurology
  • Clinical Neurology

Cite this

Medici, V., & Weiss, K. H. (2017). Genetic and environmental modifiers of Wilson disease. In Handbook of Clinical Neurology (Vol. 142, pp. 35-41). (Handbook of Clinical Neurology; Vol. 142). Elsevier B.V.. https://doi.org/10.1016/B978-0-444-63625-6.00004-5

Genetic and environmental modifiers of Wilson disease. / Medici, Valentina; Weiss, Karl Heinz.

Handbook of Clinical Neurology. Vol. 142 Elsevier B.V., 2017. p. 35-41 (Handbook of Clinical Neurology; Vol. 142).

Research output: Chapter in Book/Report/Conference proceedingChapter

Medici, V & Weiss, KH 2017, Genetic and environmental modifiers of Wilson disease. in Handbook of Clinical Neurology. vol. 142, Handbook of Clinical Neurology, vol. 142, Elsevier B.V., pp. 35-41. https://doi.org/10.1016/B978-0-444-63625-6.00004-5
Medici V, Weiss KH. Genetic and environmental modifiers of Wilson disease. In Handbook of Clinical Neurology. Vol. 142. Elsevier B.V. 2017. p. 35-41. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-444-63625-6.00004-5
Medici, Valentina ; Weiss, Karl Heinz. / Genetic and environmental modifiers of Wilson disease. Handbook of Clinical Neurology. Vol. 142 Elsevier B.V., 2017. pp. 35-41 (Handbook of Clinical Neurology).
@inbook{07da157d0c84410596927486eaa9ff6b,
title = "Genetic and environmental modifiers of Wilson disease",
abstract = "Wilson disease (WD) is characterized by remarkable variety in its phenotypic presentation. Patients with WD can present with hepatic, neurologic, and psychiatric symptoms combined in different and unpredictable ways. Importantly, no convincing phenotype–genotype correlation has ever been identified, opening the possibility that other genes, aside from ATPase copper-transporting beta (ATP7B), are involved in the pathogenesis of this condition. In addition, modifier genes, or genes that can affect the expression of other genes, may be involved. Clinical and basic science data indicate that environmental and dietary factors can potentially modify gene expression in WD and, consequently, its clinical presentation and course. In particular, previously studied genes include copper metabolism domain-containing 1 (COMMD1), antioxidant 1 copper chaperone (ATOX1), X-linked inhibitor of apoptosis (XIAP), apolipoprotein E (APOE), hemochromatosis (HFE), and 5,10-methylenetetrahydrofolate reductase (MTHFR). Dietary factors include iron and methyl group donors which could affect methionine metabolism and epigenetic mechanisms of gene expression regulation. Most of the work conducted in this field is in its initial stages but it has the potential to change the diagnosis and treatment of WD.",
keywords = "epigenetics, gender, genes, iron, modifier genes, Wilson disease",
author = "Valentina Medici and Weiss, {Karl Heinz}",
year = "2017",
doi = "10.1016/B978-0-444-63625-6.00004-5",
language = "English (US)",
volume = "142",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier B.V.",
pages = "35--41",
booktitle = "Handbook of Clinical Neurology",

}

TY - CHAP

T1 - Genetic and environmental modifiers of Wilson disease

AU - Medici, Valentina

AU - Weiss, Karl Heinz

PY - 2017

Y1 - 2017

N2 - Wilson disease (WD) is characterized by remarkable variety in its phenotypic presentation. Patients with WD can present with hepatic, neurologic, and psychiatric symptoms combined in different and unpredictable ways. Importantly, no convincing phenotype–genotype correlation has ever been identified, opening the possibility that other genes, aside from ATPase copper-transporting beta (ATP7B), are involved in the pathogenesis of this condition. In addition, modifier genes, or genes that can affect the expression of other genes, may be involved. Clinical and basic science data indicate that environmental and dietary factors can potentially modify gene expression in WD and, consequently, its clinical presentation and course. In particular, previously studied genes include copper metabolism domain-containing 1 (COMMD1), antioxidant 1 copper chaperone (ATOX1), X-linked inhibitor of apoptosis (XIAP), apolipoprotein E (APOE), hemochromatosis (HFE), and 5,10-methylenetetrahydrofolate reductase (MTHFR). Dietary factors include iron and methyl group donors which could affect methionine metabolism and epigenetic mechanisms of gene expression regulation. Most of the work conducted in this field is in its initial stages but it has the potential to change the diagnosis and treatment of WD.

AB - Wilson disease (WD) is characterized by remarkable variety in its phenotypic presentation. Patients with WD can present with hepatic, neurologic, and psychiatric symptoms combined in different and unpredictable ways. Importantly, no convincing phenotype–genotype correlation has ever been identified, opening the possibility that other genes, aside from ATPase copper-transporting beta (ATP7B), are involved in the pathogenesis of this condition. In addition, modifier genes, or genes that can affect the expression of other genes, may be involved. Clinical and basic science data indicate that environmental and dietary factors can potentially modify gene expression in WD and, consequently, its clinical presentation and course. In particular, previously studied genes include copper metabolism domain-containing 1 (COMMD1), antioxidant 1 copper chaperone (ATOX1), X-linked inhibitor of apoptosis (XIAP), apolipoprotein E (APOE), hemochromatosis (HFE), and 5,10-methylenetetrahydrofolate reductase (MTHFR). Dietary factors include iron and methyl group donors which could affect methionine metabolism and epigenetic mechanisms of gene expression regulation. Most of the work conducted in this field is in its initial stages but it has the potential to change the diagnosis and treatment of WD.

KW - epigenetics

KW - gender

KW - genes

KW - iron

KW - modifier genes

KW - Wilson disease

UR - http://www.scopus.com/inward/record.url?scp=85018542890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018542890&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63625-6.00004-5

DO - 10.1016/B978-0-444-63625-6.00004-5

M3 - Chapter

C2 - 28433108

AN - SCOPUS:85018542890

VL - 142

T3 - Handbook of Clinical Neurology

SP - 35

EP - 41

BT - Handbook of Clinical Neurology

PB - Elsevier B.V.

ER -